Omisirge is the first cellular therapy approved to treat patients with severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is low. Most… . It is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood indicated for the treatment of adults and pediatric patients 6 years or older with severe aplastic anemia following reduced intensity conditioning and for whom a compatible donor is not available. Omisirge addresses the limitations of umbilical cord blood (UCB) as a source including delayed hematopoietic recovery and increased infections and provides additional graft options for patients with severe aplastic anemia (SAA) who need hematopoietic stem cell transplant (HSCT).
Listen to this podcast episode for more information: https://www.aamds.org/podcast/dr-amandeep-salhotra-explains-tregzi-fda-approved-therapy